[1]
Li WP, Su CH, Chang YC, Lin YJ, Yeh CS. Ultrasound-induced reactive oxygen species mediated therapy and imaging using a fenton reaction activable polymersome. ACS Nano 2016; 10(2): 2017-27.
[2]
Kobayashi H, Watanabe R, Choyke PL. Improving conventional Enhanced Permeability and Retention (EPR) effects; what is the appropriate target? Theranostics 2013; 4(1): 81-9.
[3]
Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011; 153(3): 198-205.
[4]
Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013; 65(1): 71-9.
[5]
Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. Nano Today 2014; 9(2): 223-43.
[6]
Eales KL, Hollinshead KER, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 2016; 5(1): e190.
[7]
Klemm Florian, Joyce Johanna A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 2015; 25(4): 198-213.
[8]
Gasser S, Lim L, Cheung F. The role of the tumour microenvironment in immunotherapy. Endocr Relat Cancer 2017; 24(12): T283-95.
[9]
Tzu-Yin W, Wilson KE, Machtaler S, Willmann JK. Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implications. Curr Pharm Biotechnol 2013; 14(8): 743-52.
[10]
Lentacker I, De Cock I, Deckers R, De Smedt SC, Moonen CT. Understanding ultrasound induced sonoporation: definitions and underlying mechanisms. Adv Drug Deliv Rev 2014; 72: 49-64.
[11]
Dasgupta A, Liu M, Ojha T, Storm G, Kiessling F, Lammers T. Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. Drug Discov Today Technol 2016; 20: 41-8.
[12]
Abou-Elkacem L, Bachawal SV, Willmann JK. Ultrasound molecular imaging: Moving toward clinical translation. Eur J Radiol 2015; 84(9): 1685-93.
[13]
Kilroy JP, Klibanov AL, Wamhoff BR, Bowles DK, Hossack JA. Localized in vivo model drug delivery with intravascular ultrasound and microbubbles. Ultrasound Med Biol 2014; 40(10): 2458-67.
[14]
Zhao S, Borden M, Bloch SH, Kruse D, Ferrara KW, Dayton PA. Radiation-force assisted targeting facilitates ultrasonic molecular imaging. Mol Imaging 2004; 3(3): 135-48.
[15]
Miller DL, Smith NB, Bailey MR, et al. Overview of therapeutic ultrasound applications and safety considerations. J Ultrasound Med 2012; 31(4): 623-34.
[16]
Luo MH, Yeh CK, Situ B, et al. Microbubbles: A novel strategy for chemotherapy. Curr Pharm Des 2017; 23(23): 3383-90.
[17]
Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 2007; 99(14): 1095-106.
[18]
Min HS, You DG, Son S, et al. echogenic glycol chitosan nanoparticles for ultrasound-triggered cancer theranostics. Theranostics 2015; 5(12): 1402-18.
[19]
Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6(8): 583-92.
[20]
Ho YJ, Chang YC, Yeh CK. Improving nanoparticle penetration in tumors by vascular disruption with acoustic droplet vaporization. Theranostics 2016; 6(3): 392-403.
[21]
Zhao H, Wu M, Zhu L, et al. Cell-penetrating peptide-modified targeted drug-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound for precision theranostics against hepatocellular carcinoma. Theranostics 2018; 8(7): 1892-910.
[22]
Zhu L, Zhao H, Zhou Z, et al. Peptide-functionalized phase-transformation nanoparticles for low intensity focused ultrasound-assisted tumor imaging and therapy. Nano Lett 2018; 18(3): 1831-41.
[23]
Cao Y, Chen Y, Yu T, et al. Drug release from phase-changeable nanodroplets triggered by low-intensity focused ultrasound. Theranostics 2018; 8(5): 1327-39.
[24]
Huynh E, Leung BY, Helfield BL, et al. In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging. Nat Nanotechnol 2015; 10(4): 325-32.
[25]
Paefgen V, Doleschel D, Kiessling F. Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery. Front Pharmacol 2015; 6: 197.
[26]
Ma YY, Jin KT, Wang SB, et al. Molecular imaging of cancer with nanoparticle-based theranostic probes. Contrast Media Mol Imaging 2017; 2017: 1026270.
[27]
Ma J, Xu CS, Gao F, et al. Diagnostic and therapeutic research on ultrasound microbubble/nanobubble contrast agents.(Review). Mol Med Rep 2015; 12(3): 4022-8.
[28]
Xing L, Shi Q, Zheng K, et al. Ultrasound-mediated microbubble destruction (ummd) facilitates the delivery of ca19-9 targeted and paclitaxel loaded mpeg-plga-pll nanoparticles in pancreatic cancer. Theranostics 2016; 6(10): 1573-87.
[29]
Cerroni B, Chiessi E, Margheritelli S, Oddo L, Paradossi G. Polymer shelled microparticles for a targeted doxorubicin delivery in cancer therapy. Biomacromolecules 2011; 12(3): 593-601.
[30]
Liu H, Chang S, Sun J, et al. Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles induces proliferation inhibition and apoptosis in ovarian cancer cells. Mol Pharm 2014; 11(1): 40-8.
[31]
Wu M, Wang Y, Wang Y, et al. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer. Int J Nanomedicine 2017; 12: 5313-30.
[32]
An L, Hu H, Du J, et al. Paramagnetic hollow silica nanospheres for in vivo targeted ultrasound and magnetic resonance imaging. Biomaterials 2014; 35(20): 5381-92.
[33]
Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 2012; 39(Suppl. 1): S126-38.
[34]
Deng Z, Xiao Y, Pan M, et al. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound. J Control Release 2016; 243: 333-41.
[35]
Luo W, Wen G, Yang L, et al. Dual-targeted and ph-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment. Theranostics 2017; 7(2): 452-65.
[36]
Lin W, Xie X, Deng J, et al. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery. J Drug Target 2016; 24(2): 134-46.
[37]
Trendowski M. The promise of sonodynamic therapy. Cancer Metastasis Rev 2014; 33(1): 143-60.
[38]
Li Y, An H, Wang X, et al. Ultrasound-triggered release of sinoporphyrin sodium from liposome-microbubble complexes and its enhanced sonodynamic toxicity in breast cancer. Nano Res 2018; 11(2): 1038-56.
[39]
Wang X, Liu P, Yang W, et al. Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood-brain barrier. Int J Nanomedicine 2014; 9((issue 1)): 4899.
[40]
Zhao Y, Lin Q, Wong HL, et al. Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery. J Control Release 2016; 224: 112-25.
[41]
Fan CH, Cheng YH, Ting CY, et al. Ultrasound/magnetic targeting with spio-dox-microbubble complex for image-guided drug delivery in brain tumors. Theranostics 2016; 6(10): 1542-56.
[42]
Huang P, You X, Pan M, et al. A novel therapeutic strategy using ultrasound mediated microbubbles destruction to treat colon cancer in a mouse model. Cancer Lett 2013; 335(1): 183-90.
[43]
Zhang C, Huang P, Zhang Y, et al. Anti-tumor efficacy of ultrasonic cavitation is potentiated by concurrent delivery of anti-angiogenic drug in colon cancer. Cancer Lett 2014; 347(1): 105-13.
[44]
Moen I, Stuhr LEB. Hyperbaric oxygen therapy and cancer—a review. Target Oncol 2012; 7(4): 233-42.
[45]
Yang C, Xiao H, Sun Y, et al. Lipid microbubbles as ultrasound-stimulated oxygen carriers for controllable oxygen release for tumor reoxygenation. Ultrasound Med Biol 2018; 44(2): 416-25.
[46]
Liu L, Chang S, Sun J, et al. Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts. Cancer Lett 2015; 361(1): 147-54.
[47]
Zhang K, Xu H, Chen H, et al. CO2 bubbling-based ‘Nanobomb’ System for Targetedly Suppressing Panc-1 Pancreatic Tumor via Low Intensity Ultrasound-activated Inertial Cavitation. Theranostics 2015; 5(11): 1291-302.
[48]
Min KH, Min HS, Lee HJ, et al. pH-controlled gas-generating mineralized nanoparticles: a theranostic agent for ultrasound imaging and therapy of cancers. ACS Nano 2015; 9(1): 134-45.
[49]
Carpenter AW, Schoenfisch MH. Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev 2012; 41(10): 3742-52.
[50]
Zhang K, Xu H, Jia X, et al. Ultrasound-triggered nitric oxide release platform based on energy transformation for targeted inhibition of pancreatic tumor. ACS Nano 2016; 10(12): 10816-28.
[51]
Wang B, Zhai Y, Shi J, et al. Simultaneously overcome tumor vascular endothelium and extracellular matrix barriers via a non-destructive size-controlled nanomedicine. J Control Release 2017; 268: 225-36.
[52]
Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age. Science 2018; 359(6372): n4672.
[53]
Huang C, Zhang H, Bai R. Advances in ultrasound-targeted microbubble-mediated gene therapy for liver fibrosis. Acta Pharm Sin B 2017; 7(4): 447-52.
[54]
Bykov V, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. NAT REV CANCER 2018; 18(2): 89-102.
[55]
Chang S, Guo J, Sun J, et al. Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells. Ultrason Sonochem 2013; 20(1): 171-9.
[56]
Gao R, Zhou X, Yang Y, Wang Z. Transfection of wtp53 and Rb94 genes into retinoblastomas of nude mice by ultrasound-targeted microbubble destruction. Ultrasound Med Biol 2014; 40(11): 2662-70.
[57]
Fan CH, Chang EL, Ting CY, et al. Folate-conjugated gene-carrying microbubbles with focused ultrasound for concurrent blood-brain barrier opening and local gene delivery. Biomaterials 2016; 106: 46-57.
[58]
Chang EL, Ting CY, Hsu PH, et al. Angiogenesis-targeting microbubbles combined with ultrasound-mediated gene therapy in brain tumors. J Control Release 2017; 255: 164-75.
[59]
Nana-Sinkam SP, Croce CM. MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol 2014; 15(9): 445.
[60]
Li T, Sun X, Xu K. The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway. Cell Biosci 2018; 8: 17.
[61]
Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 2017; 35(3): 222-9.
[62]
Devulapally R, Sekar NM, Sekar TV, et al. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano 2015; 9(3): 2290-302.
[63]
Wang TY, Choe JW, Pu K, et al. Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. J Control Release 2015; 203: 99-108.
[64]
Chen W, Du J, Li X, et al. miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics 2017; 18(18): 1671-82.
[65]
Mullick CS, Wang TY, Bachawal S, et al. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release 2016; 238: 272-80.
[66]
Lin L, Fan Y, Gao F, et al. UTMD-promoted co-delivery of gemcitabine and mir-21 inhibitor by dendrimer-entrapped gold nanoparticles for pancreatic cancer therapy. Theranostics 2018; 8(7): 1923-39.
[67]
Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J 2017; 474(24): 4219-51.
[68]
Babu A, Muralidharan R, Amreddy N, et al. Nanoparticles for siRNA-based gene silencing in tumor therapy. IEEE Trans Nanobioscience 2016; 15(8): 849-63.
[69]
Zajac M, Muszalska I, Jelinska A. New molecular targets of anticancer therapy-current status and perspectives. Curr Med Chem 2016; 23(37): 4176-220.
[70]
Liang J, Huang W, Cai W, et al. Inhibition of microRNA-495 enhances therapeutic angiogenesis of human induced pluripotent stem cells. Stem Cells 2017; 35(2): 337-50.
[71]
Frinking PJ, Tardy I, Theraulaz M, et al. Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent. Ultrasound Med Biol 2012; 38(8): 1460-9.
[72]
Florinas S, Kim J, Nam K, Janat-Amsbury MM, Kim SW. Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release 2014; 183: 1-8.
[73]
Lyu H, Huang J, He Z, Liu B. Epigenetic mechanism of survivin dysregulation in human cancer. Sci China Life Sci 2018.
[74]
Li J, Cheng D, Yin T, et al. Copolymer of poly(ethylene glycol) and poly(L-lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery. Nanoscale 2014; 6(3): 1732-40.
[75]
Zhang Y, Chang S, Sun J, et al. Targeted microbubbles for ultrasound mediated short hairpin rna plasmid transfection to inhibit survivin gene expression and induce apoptosis of ovarian cancer A2780/DDP Cells. Mol Pharm 2015; 12(9): 3137-45.
[76]
Chen ZY, Liang K, Lin Y, Yang F. Study of the UTMD-based delivery system to induce cervical cancer cell apoptosis and inhibit proliferation with shRNA targeting Survivin. Int J Mol Sci 2013; 14(1): 1763-77.
[77]
Wang P, Yin T, Li J, et al. Ultrasound-responsive microbubbles for sonography-guided siRNA delivery. Nanomedicine-UK 2016; 12(4): 1139-49.
[78]
Wu B, Qiao Q, Han X, et al. Targeted nanobubbles in low-frequency ultrasound-mediated gene transfection and growth inhibition of hepatocellular carcinoma cells. Tumour Biol 2016; 37(9): 12113-21.
[79]
Bae YJ, Yoon YI, Yoon TJ, Lee HJ. Ultrasound-guided delivery of sirna and a chemotherapeutic drug by using microbubble complexes: In Vitro and in vivo evaluations in a prostate cancer model. Korean J Radiol 2016; 17(4): 497-508.
[80]
Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9(1): 47-59.
[81]
Yin T, Wang P, Li J, et al. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials 2014; 35(22): 5932-43.
[82]
Scherman D, Rousseau A, Bigey P, Escriou V. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications. Gene Ther 2017; 24(3): 151-6.
[83]
Zhao G, Huang Q, Wang F, et al. Targeted shRNA-loaded liposome complex combined with focused ultrasound for blood brain barrier disruption and suppressing glioma growth. Cancer Lett 2018; 418: 147-58.
[84]
Matkar PN, Singh KK, Prud Homme GJ, Hedley DW, Leong-Poi H. Abstract 2919: Ultrasound-mediated neuropilin-1 shRNA minicircle delivery inhibits tumour growth in an orthotopic human pancreatic adenocarcinoma model. Cancer Res 2016; 76(14)(Suppl.): 2919.
[85]
Zhou R, Curry JM, Roy LD, et al. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Oncogene 2016; 35(43): 5608-18.
[86]
Carpentier A, Canney M, Vignot A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med 2016; 8(343): 342r-3r.
[87]
Dimcevski G, Kotopoulis S, Bjanes T, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release 2016; 243: 172-81.
Download PDF Flyer